Clal Biotechnology Industries Ltd Total Liabilities
Clal Biotechnology Industries Ltd total liabilities. Based on the latest financial reports, Clal Biotechnology Industries Ltd (CBI) has total liabilities worth ILA19.52 Million ILA (≈ $52.33K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Clal Biotechnology Industries Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Clal Biotechnology Industries Ltd (2006–2024)
Total liabilities of Clal Biotechnology Industries Ltd from 2006 to 2024. This chart illustrates how Clal Biotechnology Industries Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Clal Biotechnology Industries Ltd (CBI) investment intensity to see how much of total assets are deployed in long-term investments.
Clal Biotechnology Industries Ltd Competitors by Total Liabilities
The table below lists competitors of Clal Biotechnology Industries Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SSH Group Ltd
AU:SSH
|
Australia | AU$31.15 Million |
|
Asra Minerals Ltd
AU:ASR
|
Australia | AU$2.99 Million |
|
Peruvian Metals Corp
V:PER
|
Canada | CA$631.62K |
|
US Copper Corp
V:USCU
|
Canada | CA$49.46K |
|
Bitterroot Resources Ltd
V:BTT
|
Canada | CA$747.87K |
|
Regentis Biomaterials Ltd.
NYSE:RGNT
|
USA | $2.87 Million |
|
CHINA GREEN AGRIC.DL-001
F:GR0A
|
Germany | €68.81 Million |
|
EAM Solar ASA
OL:EAM
|
Norway | Nkr8.52 Million |
Liability Composition Analysis (2006–2024)
This chart breaks down Clal Biotechnology Industries Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Clal Biotechnology Industries Ltd assets under control.
Liquidity & Leverage Metrics
Clal Biotechnology Industries Ltd Total Liabilities Ratios Explained
Clal Biotechnology Industries Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Clal Biotechnology Industries Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Clal Biotechnology Industries Ltd (2006–2024)
The table below shows the annual total liabilities of Clal Biotechnology Industries Ltd from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA21.52 Million ≈ $57.70K |
-41.80% |
| 2023-12-31 | ILA36.98 Million ≈ $99.14K |
-2.16% |
| 2022-12-31 | ILA37.79 Million ≈ $101.32K |
-64.53% |
| 2021-12-31 | ILA106.55 Million ≈ $285.65K |
+6.29% |
| 2020-12-31 | ILA100.24 Million ≈ $268.74K |
-15.85% |
| 2019-12-31 | ILA119.12 Million ≈ $319.35K |
-19.76% |
| 2018-12-31 | ILA148.46 Million ≈ $398.02K |
-34.35% |
| 2017-12-31 | ILA226.14 Million ≈ $606.28K |
-38.25% |
| 2016-12-31 | ILA366.21 Million ≈ $981.81K |
-16.83% |
| 2015-12-31 | ILA440.31 Million ≈ $1.18 Million |
+2.77% |
| 2014-12-31 | ILA428.44 Million ≈ $1.15 Million |
-20.72% |
| 2013-12-31 | ILA540.45 Million ≈ $1.45 Million |
+52.59% |
| 2012-12-31 | ILA354.19 Million ≈ $949.58K |
+149.42% |
| 2011-12-31 | ILA142.01 Million ≈ $380.71K |
+2.75% |
| 2010-12-31 | ILA138.20 Million ≈ $370.51K |
-9.91% |
| 2009-12-31 | ILA153.41 Million ≈ $411.28K |
+1.28% |
| 2008-12-31 | ILA151.47 Million ≈ $406.08K |
+36.48% |
| 2007-12-31 | ILA110.98 Million ≈ $297.54K |
+787.86% |
| 2006-12-31 | ILA12.50 Million ≈ $33.51K |
-- |
About Clal Biotechnology Industries Ltd
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It prefers to invest in life sciences, medical devices, biopharmaceutical technologies, and biotechnology companies. The firm seeks to i… Read more